Euroscreen is a Gosselies, Belgium-based drug development company led by CEO Jean Combalbert. The company is advancing ESN364, a proprietary oral small-molecule candidate for the treatment of women's health disorders. ESN364 has shown promising expectations in treating menopausal hot flashes and other conditions including polycystic ovary syndrome (PCOS), uterine fibroids (UF) and endometriosis. Euroscreen is supporting ongoing Phase II clinical trials of ESN364 versus menopausal hot flashes, PCOS and UF. The company plans to use recently raised funds to file an IND in the US and to perform long-term toxicology studies to support future chronic treatment trials. It completed a €16m Series B round to finance these development activities. Euroscreen SA develops novel G protein-coupled receptor (GPCR) drug concepts, including next-generation sex hormone control in women’s health. Its lead clinical candidate is ESN364, an advanced product for the treatment of endometriosis, and the company intends to use the Series A proceeds to advance this program. Euroscreen started as a spin-off of ULB (Université Libre de Bruxelles) and is led by CEO Jean Combalbert. It maintains research and licensing partnerships with pharmaceutical companies including Boehringer‑Ingelheim, Cephalon, Grünenthal, HGS, Ortho‑McNeil‑Janssen, Monogram Biosciences, Novartis and Pfizer. The company offers a broad patent portfolio for targets and screening tools and is actively seeking collaborations to advance additional pharmaceutical candidates. Targets in its portfolio include CCR5, ChemR23, GPR43, GPR7/8, ORL1‑R, FPRL2, P2Y4, P2Y11 and P2Y13.

Total raised

$31M

Funding rounds

2

Latest round

Series B

Latest activity

Oct 2015